期刊文献+

多西他赛和紫杉醇分别联合顺铂用于局部晚期宫颈癌新辅助化疗的近期疗效观察 被引量:16

Short-term therapeutic effect of neoadjuvant chemotherapy with docetaxel or paclitaxel plus cisplatin before radical hysterectomy on locally advanced cervical cancer
下载PDF
导出
摘要 目的探讨多西他赛(DTX)联合顺铂(DDP)与紫杉醇(TAX)联合DDP用于ⅠB2期—ⅡB期局部晚期宫颈癌(LACC)患者术前新辅助化疗(NACT)的近期疗效与不良反应。方法回顾性分析经组织病理学活检确诊为ⅠB2期—ⅡB期宫颈癌的106例患者。分为DP组(n=54,DTX 75 mg/m^2+DDP 75 mg/m^2)和TP组(n=52,TAX 135 mg/m^2DDP 75 mg/m^2),两组均在宫颈癌根治术前给予2次NACT,比较效果、毒副反应及术后切除标本的病理结果。结果 DP组化疗后有效率为90.7%,TP组的化疗有效率为84.6%,两者比较差异无显著性(P>0.05)。DP组白细胞减少明显低于TP组,差异具有显著性(P<0.05),两组间Hb减少,差异无显著性(P>0.05);DP组神经毒性反应、胃肠道反应较TP组轻,差异有显著性(P<0.05),两组间脱发、肝肾脏毒性反应差异无显著性(P>0.05)。两组术后标本病理组织检查,完全缓解率和理想的病理反应率及宫旁浸润、盆腔淋巴结阳性率等方面比较,差异均无显著性(P>0.05)。结论 DTX+DDP方案与TAX+DDP方案在宫颈癌NACT的近期效果相近,但DTX+DDP方案的不良反应较轻,值得推荐。 Objective To investigate the efficacy and adverse reactions of neoadjuvant chemotherapy of docetaxel(DTX) or paclitaxel(TAX) plus cisplatin(DDP) before radical hysterectomy on patients with stageⅠB2-ⅡB locally advanced cervicalcancer. Methods 106 patients with stage ⅠB2-ⅡB cervical cancer who were treated with different chemotherapy regimens were retrospectively analyzed. The patients were divided into DP group(n=54,DTX 75 mg /m^2+ DDP 75 mg /m^2)and TP group(n=52,TAX 135 mg /m^2+ DDP75 mg /m^2). All of the patients were given two cycles of neoadjuvant chemotherapy. The efficacy, side effects of neoadjuvant chemotherapy and pathological examination after hysterectomy were compared between two groups. Results There was no significant difference in chemotherapy efficacy between the two groups(90.7% vs 84.6%,P〈0.05). The side effects of neoadjuvant chemotherapy: the incidence of leucopenia in DP group were lower than that in TP group(P〈0.05). There were no significant differences in hemoglobin,alopecia, hepatic renal toxicity between two groups(P〈0.05). The gastroenteric and neurotoxicity reactions in DP group were lower than those in TP group(P〈0.05). There were no significant difference(P〈0.05) between two groups in pathological complete remission rate, ideal pathological response rate, parametrial invasion, positive rate of pelvic lymph nodes etc(P〈0.05). Conclusion The neoadjuvant chemotherapy of both DTX or TAX plus DDP have similar efficacy in the treatment of locally advanced cervical cancer,and the adverse reactions of DTX plus DDP is mild, is worth to be recommended in locally advanced cervical cancer.
出处 《兰州大学学报(医学版)》 CAS 2016年第3期38-42,共5页 Journal of Lanzhou University(Medical Sciences)
关键词 多西他赛 紫杉醇 顺铂 新辅助化疗 局部晚期宫颈癌 docetaxel Paclitaxel cisplatin neoadjuvant chemotherapy locally advanced cervical cancer
  • 相关文献

参考文献18

  • 1Papadia A, Bellati F, Bogani G, et al. When does neoadju- vant chemotherapy really avoid radiotherapy? clinical pre- dictors of adjuvant radiotherapy in cervical cancer[J]. Annals of Surgical Oncology, 2015, 22( Suppl 3): 944- 951.
  • 2Zhang H, Peng W, Zhang Y. Detection of cell apoptosis in pelvic lymph nodes of patients with cervical cancer after neoadjuvant chemotherapy[J]. The Journal of International Medical Research, 2014, 42(3 ): 641-650.
  • 3Peng Y H, Wang X X, Zhu J S, et al. Neo-adjuvant chemo- therapy plus surgery versus surgery alone for cervical cancer: Meta- analysis of randomized controlled trials[J]. The Journal of Obstetrics and Gynaecology Research, 2016, 42(2): 128-135.
  • 4Duffaud F, Therasse P. New guidelines to evaluate the re- sponse to treatment in solid tumors[J]. Bulletin du Cancer, 2000, 87(12): 881-886.
  • 5Singh U, Ahirwar N, Rani A K, et al. The efficacy and safety of neoadjuvant chemotherapy in treatment of local- ly advanced carcinoma cervix[J]. Journal of Obstetrics and Gynaecology of India, 2013, 63(4): 273-278.
  • 6Scandurra G, Scibilia G, Banna G L, et al. Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma[J]. Journal of Gynecologic Oncology, 2015, 26(2): 118-124.
  • 7Abou-Taleb H A, Koshiyama M, Matsumura N, et al. Clin- ical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterecto- my for locally advanced cervical cancer[J]. The Journal of International Medical Research, 2016, 44(2): 346-356.
  • 8Lapresa M, Parma G, Portuesi R, et al. Neoadjuvant che- motherapy in cervical cancer: an update[J]. Expert Reviewof Anticancer Therapy, 2015, 15(10): 1171-1181.
  • 9Tsunoda A T, Andrade C E, Vieira M A, et al. Laparsco- py in uterine cervical cancer: current state and literature review[J]. Revista do Colegio Brasileiro de Cirurgioes, 2015, 42(5): 345-351.
  • 10Mabuchi S, Isohashi F, Yokoi T, et al. A phase 11 study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes[J]. Gynecologic Oncology, 2016, S0090- 8258(16): 30035-X.

同被引文献129

引证文献16

二级引证文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部